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a  b  s  t  r  a  c  t
The  family  of lysosome-associated  membrane  proteins  (LAMP)  includes  the  ubiquitously  expressed
LAMP1  and  LAMP2,  which  account  for  half  of  the proteins  in the  lysosomal  membrane.  Another  member
of the  LAMP  family  is  LAMP3,  which  is expressed  only  in  certain  cell  types  and differentiation  stages.
LAMP3  expression  is  linked  with  poor  prognosis  of certain  cancers,  and  the  locus  where  it is encoded  was
identiﬁed  as  a risk  factor  for Parkinson’s  disease  (PD).  Here,  we investigated  the  role  of LAMP3  in  the  two
main  cellular  degradation  pathways,  the  proteasome  and  autophagy.  LAMP3  mRNA  was not  detected  in
mouse  models  of  PD  or in the  brain  of  human  patients.  However,  it was  strongly  induced  upon  proteaso-




inhibition  was  dependent  on  UPR transcription  factor  ATF4  signaling  and  induced  autophagic  ﬂux.  Pre-
vention  of LAMP3  induction  enhanced  apoptotic  cell  death.  In summary,  these  data  demonstrate  that
LAMP3  regulation  as  part of  the  UPR contributes  to protein  degradation  and  cell  survival  during  protea-
somal  dysfunction.  This  link  between  autophagy  and  the proteasome  may  be of special  importance  for
the treatment  of  tumor  cells  with  proteasomal  inhibitors.
© 2015  The  Authors.  Published  by  Elsevier  GmbH.  This  is  an  open  access  article  under  the  CCntroduction
The ubiquitin-proteasome system and the autophagic-
ysosomal pathway are the two major degradation systems
or proteins in eukaryotic cells. They are responsible for the degra-
ation of unnecessary, dysfunctional or damaged components,
rom soluble proteins to protein aggregates and whole organelles
Korolchuk et al., 2010). The ubiquitin-proteasome system medi-
tes the enzymatic ubiquitination of substrate proteins. The tagged
roteins are then recognized by a barrel-shaped structure called
he proteasome, in which they are degraded to peptides (Glickman
Abbreviations: CCCP, carbonyl cyanide m-chlorophenyl hydrazone; DMSO,
imethyl sulfoxide; FCS, fetal calf serum; GFP, green ﬂuorescent protein; HBSS,
ank’s Balanced Salt Solution; LAMP, lysosome-associated membrane protein; LC3,
icrotubule-associated protein light chain 3; PARP, poly ADP ribose polymerase;
D,  Parkinson’s disease; ROI, region of interest; UPR, unfolded protein response.
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and Ciechanover, 2002). Autophagic-lysosomal degradation can be
classiﬁed into macroautophagy, chaperone mediated autophagy
and microautophagy. In macroautophagy (usually referred to as
autophagy) the substrate cargo is engulfed by the autophagosome,
which is characterized by the presence of the protein LC3-II.
Once the cargo is completely surrounded by the autophago-
some, this double-membrane organelle fuses with the lysosome,
where proteolysis occurs (He and Klionsky, 2009; Mizushima,
2007).
The ubiquitin-proteasome system and autophagy do not act
independently from each other. Defective autophagy results in
accumulation of ubiquitinated proteins, impacting the ﬂux of the
ubiquitin proteasome system. On the other hand, dysfunction of the
proteasome can promote a compensatory induction of autophagy
(Korolchuk et al., 2010; Nedelsky et al., 2008).
Lysosomal function depends on lysosomal hydrolases and inte-
gral lysosomal membrane proteins. Over 25 lysosomal membrane
proteins are known, which participate in diverse tasks such as lyso-
somal acidiﬁcation, membrane fusion and transport of degradation
products to the cytoplasm (Saftig and Klumperman, 2009). The
family of lysosome-associated membrane proteins (LAMP) includes
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ve members: LAMP1, LAMP2, LAMP3, BAD-LAMP and macrosialin
CD68/LAMP4), which share a so-called LAMP domain and possess
everal N- and O-glycosylation sites (Saftig et al., 2010; Wilke et al.,
012).
LAMP1 and LAMP2 represent about 50% of the lysosomal mem-
rane proteins (Saftig et al., 2010). They are type-1 transmembrane
roteins with high sequence homology, containing a highly gly-
osylated luminal domain and a short cytosolic tail (Saftig and
lumperman, 2009). The generation of LAMP1 knockout mice
esulted in mild regional brain astrogliosis and upregulation of
AMP2 at the protein level. However, the distribution and den-
ity of lysosomes, as well as lysosomal enzyme activity, pH and
smotic stability were unaffected (Andrejewski et al., 1999). On
he other hand, LAMP2 knockout mice showed increased mortality
etween 20 and 40 days of age, with the surviving mice being fertile
nd having a normal life span, although they showed accumula-
ion of autophagic vacuoles in several tissues (Tanaka et al., 2000).
 LAMP1/LAMP2 double knockout resulted in embryonic death
etween E14.5 and E16.5. Fibroblasts derived from those double
nockout embryos showed accumulation of autophagic vacuoles
nd of LC3-II after amino acid starvation, indicating impairment of
utophagic ﬂux (Eskelinen et al., 2004).
Unlike the ubiquitous LAMP1 and LAMP2, LAMP3 (also called
C-LAMP, CD208, or TSC403) is expressed only in speciﬁc tissues
nd conditions. Early reports on LAMP3 showed that it is induced
pon human dendritic cell differentiation (de Saint-Vis et al., 1998),
hat it is present in normal and transformed human type II pneu-
ocytes (Akasaki et al., 2004; Salaun et al., 2004), and is increased
n carcinomas of different origin, where it has been linked to metas-
asis of tumor cells and poor prognosis (Kanao et al., 2005; Ozaki
t al., 1998).
Additionally, despite the lack of evidence for LAMP3 expression
n brain tissue (Akasaki et al., 2004; de Saint-Vis et al., 1998), several
enome-wide association studies have identiﬁed the chromoso-
al  locus MCCC1/LAMP3 associated with increased risk for sporadic
ld-age Parkinson’s disease (PD) (Li et al., 2013; Lill et al., 2012;
ihlstrom et al., 2013). Finally, LAMP3 was shown to be involved in
he unfolded protein response (UPR) during hypoxia (Nagelkerke
t al., 2013a), while its localization points to a possible function in
utophagic-lysosomal degradation.
As recent data indicate that the autophagic-lysosomal pathway
nd the ubiquitin-proteasome system act together to maintain pro-
ein homeostasis (Korolchuk et al., 2010; Park and Cuervo, 2013;
ogl et al., 2014), we evaluated the hypothesis that LAMP3 repre-
ents a link between these two systems.
aterials and methods
ell culture
HeLa cells were cultured in Minimal Essential Medium with
arle’s salts (Gibco) supplemented with 1× MEM  Non-Essential
minoacids (Gibco), 10% FCS Gold (PAA), and 10 mM HEPES buffer
0 mM (PAA). Neuroblastoma SH-SY5Y cells were cultured in
PMI 1640 medium (Gibco) supplemented with 10% FCS (PAA).
oth cell lines were kept at 37 ◦C, 5% CO2 and 95% air. SH-SY5Y
ells were cultured with the following drugs at the indicated
nal concentration: U0126 10 M,  LY294002 25 M, CCCP 10 nM,
apamycin 0.5 M,  staurosporine 30 nM,  baﬁlomycin A1 10 nM,  3-
ethyladenine 10 mM,  MG132 3 M or 300 nM,  epoxomicin 1 M,
hapsigargin 1 M,  and tunicamycin 1 g/ml. DMSO was included
s control at a ﬁnal concentration of 0.05%. Cells were deprived
f amino acids by culturing them in Hank’s Balanced Salt Solution
BSS (Gibco). Differentiation of SH-SY5Y cells was performed by
ulturing cells at a density of 52 000 cells/cm2 in RPMI mediumrnal of Cell Biology 94 (2015) 148–161 149
supplemented with 3% FCS and 10 M retinoic acid for 10 days.
New medium was  added every other day.
Infusion of mouse brains with epoxomicin
Infusion of mice midbrains was  performed as described else-
where (Subramaniam et al., 2014). Brieﬂy, 4 l of epoxomicin
(10 M)  or DMSO (1%) were unilaterally injected into the substantia
nigra of 11-week old mice. Either 24 h or 2 weeks post-injection, the
mice were euthanized. The midbrain (including substantia nigra) of
the injected side was  immediately dissected, frozen in liquid nitro-
gen, and stored at −80 ◦C. Total RNA was isolated using the TRI®
reagent, and qRT-PCR analysis was  performed as described below.
Post-mortem samples of human brain
Brain tissue samples from autopsy-conﬁrmed subjects with
Parkinson’s disease with Braak stage 6 (n = 6) of -synuclein
pathology and age-/gender-matched controls (n = 4, Supplemen-
tary Table 1) were obtained from the Neurobiobank Munich with
approval of the Frankfurt University Medical school ethics com-
mittee. Pathological analysis was performed according to the Lewy
Body Dementia staging (Braak et al., 2003). At ages above 60 years,
all PD and control cases had some Alzheimer-associated neuroﬁb-
rillary tangle pathology (Braak and Braak, 1991). The PD cases had
conﬁrmed -synuclein pathology in the cingulate gyrus, while the
controls were chosen so that no -synuclein-, amyloid-beta- or
MAP-tau-pathology was  detectable in this brain region (Thal et al.,
2002). Gray matter from the posterior cingulate gyrus next to the
posterior thalamus was  dissected for total RNA and protein isola-
tion.
Total protein was obtained from ∼150 mg of tissue by serial
isolation. First, the tissue was  homogenized with a Dounce tissue
grinder (Wheaton) and 10 volumes of RIPA buffer (50 mM Tris–HCl
pH 7, 150 mM  NaCl, 0.1% SDS, 1% Triton X-100, 0.5% sodium
deoxycholate, 2 mM EDTA, and 1× protease inhibitors). Lysate was
centrifuged at 9000 × g for 10 min  at 4 ◦C and the RIPA-insoluble
pellet was then lysed with 2× SDS buffer (137 mM Tris–HCl pH 6.8,
4% sodium dodecyl sulfate, 20% glycerol, 1× protease inhibitors),
sonicated for 10 s with a homogenizer (Bandelin) and centrifu-
gated at 9000 × g for 10 min. The 2× SDS-soluble fraction contains
membrane-associated proteins and was used for LAMP3 western
blot. Total RNA was  isolated from ∼50 mg  of tissue using the TRI®
reagent. RNA integrity was determined using the Agilent RNA 6000
Pico Kit and the Agilent 2100 Bioanalyzer (Agilent). Gene expres-
sion was  measured by qRT-PCR as indicated below.
Plasmid, siRNAs, and cell transfection
A plasmid coding for LAMP3 with enhanced green ﬂuorescent
protein fused at the C-terminal end (LAMP3-GFP) was gener-
ated by subcloning the open reading frame of human LAMP3
(NM 014398.3) into the XmnI and NotI restriction sites of vec-
tor pEZ-M03, under the control of the Cytomegalovirus promoter
(GeneCopoeia).
The siRNAs AllStars Negative Control (1027281), Hs LAMP3 5
(SI041532226), Hs LAMP3 7 (SI04287458), and Hs ATF4 5
(SI03019345) from QIAGEN were used.
The Amaxa Cell Line Nucleofector kit V and the NucleofectorTM
2b Device (Lonza) were used to transfect 1.5 × 106 SH-SY5Y
cells with 0.1 nmol of siRNAs according to the manufacturer’s
instructions. Transfection of HeLa cells was performed by plat-
ing 250 000 cells on gelatin-coated 24-mm coverslips. Cells were
transfected using 1 g of plasmid with the Effectene kit (QIAGEN)
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DNA synthesis and quantitative RT-PCR
Total RNA from cells was isolated using the RNeasy Mini
it (QIAGEN) according to manufacturer’s instructions. One
icrogram of total RNA was used for cDNA synthesis using the
uperScript III Reverse transcriptase (Life Technologies). Quan-
itative Real Time Polymerase Chain Reaction (qRT-PCR) was
erformed in a Step One Plus Real Time PCR System (Life Techno-
ogies) using the following TaqMan assays: LAMP1 (Hs00931-
64 m1), LAMP2 (Hs00903587 m1,  which detects the LAMP2A,
AMP2B, and LAMP2 C isoforms), LAMP3 (Hs01111317 m1), ATG5
Hs00355494 m1), BECN1 (Hs00186838 m1), ATG7 (Hs00197-
48 m1), DDIT3 (Hs00358796 g1), HSPA5 (Hs99999174 m1), ATF3
Hs00231069 m1), ATF4 (Hs00909569 g1), SQSTM1 (Hs001776-
4 m1), PINK1 (Hs00260868 m1), PARKIN (Hs01038318 m1), ATP-
3A2 (Hs01119446 m1), DJ-1 (Hs00697109 m1), SNCA (Hs011033-
6 m1), ATNX2 (Hs00268077 m1), EIF4A2 (Hs01115195 g1), SYT11
Hs01064643 m1), CPLX1 (Hs00362510 m1), NSF (Hs009380-
0 m1), RAB7L1 (Hs01026316 m1), RAB25 (Hs01040784 m1), GAK
Hs01049227 m1), BST1 (Hs 01070189 m1), STK39 (Hs010853-
6 m1), HIP1R (Hs00391321 m1), EIF4A2 (Hs01115195 g1),
APDH (Hs99999905 m1), TBP (Hs99999910 m1), Lamp3
Mm00616604 m1), and Tbp (Mm00446973 m1). TBP or Tbp
ere used as human or mouse housekeeping genes, correspond-
ngly. Relative gene expression was calculated using the 2−Ct
ormula.
estern blot
Total protein was isolated with 2× SDS lysis buffer (137 mM
ris–HCl pH 6.8, 4% sodium dodecyl sulfate, 20% glycerol, 1× pro-
ease inhibitors). The cell lysate was sonicated for 10 s with a
omogenizer (Bandelin) and centrifugated at 9000 × g for 10 min.
upernatant was collected and protein concentration was deter-
ined with a protein quantitation kit (Interchim) using bovine
erum albumin as standard. Human lung tissue lysate was  obtained
rom Novus biologicals. 15–30 g of total protein lysate were
eparated by SDS-PAGE, transferred to a PVDF membrane, and
locked with 5% skim milk in 1× PBS/0.1% Tween. For analy-
is of brain tissue, 15 g of protein were separated using 4–12%
is–Tris pre-cast gels (Novex). Membranes were probed using
he following primary antibodies: LC3 (Sigma), SQSTM1 (Santa
ruz), PARP (Cell Signaling), GFP (Living Colors), and GAPDH (Cal-
iochem). The following LAMP3 antibodies were used: ab83659
Abcam), AF4087 (R&D systems), MABC44 (Millipore), and 10527-
P02 (Sino Biological Inc.). Secondary antibodies were conjugated
ith horseradish-peroxidase, and detection was performed with
est pico chemiluminescent Super Signal Substrate. Band intensity
as quantiﬁed using the ImageJ software.
rotein deglycosylation
Protein lysates were obtained using a deglycosylation lysis
uffer (50 mM Tris HCl pH 7.4, 150 mM NaCl, 1% IGEPAL, 0.5%
eoxycholate acid, 0.1 mM  EDTA, 1× Protease inhibitor cocktail).
0 g of protein were used for deglycosylation using PNGase
, which removes N-glycosylation; or with deglycosylation mix,
hich removes N- and O-glycosylation (New England Biolabs)
ccording to supplier instructions. Molecular weight shifts were
nalyzed by western blot.
aspase-3 activity assayCells were lysed in caspase-3 lysis buffer (10 mM HEPES pH
.4, 150 mM  NaCl, 1 mM EDTA, 0.5% Chaps, 1 mM Dithiothrietol,
 g/ml Pepstatin A, and 1 mM PMSF). Cells were sonicated andrnal of Cell Biology 94 (2015) 148–161
the lysate was  centrifuged at 9000 × g for 10 min. Supernatant was
collected and the protein concentration was determined by the
Bradford method using bovine serum albumin as reference.
Between 1 and 5 g of protein were mixed with caspase-3 reac-
tion buffer (25 mM HEPES pH 7.4, 1 mM EDTA, 0.1% Chaps, 1 mM
DTT, 10 M AC-DEVD-AMC, and 8.6% d(+)-Sucrose). Fluorescence
intensity was  measured every 10 min  over the course of 2 h using
excitation at 360 nm and emission at 465 nm in a GENios microplate
reader (Tecan).
Confocal laser scanning microscopy and immunostaining
Cells were cultured on gelatin-coated coverslips, ﬁxed with
4% paraformaldehyde for 20 min, washed 3 times with phosphate
buffered Saline 1× (PBS 1×), permeabilized with 0.1% Triton X-100
for 20 min, washed 3 times with PBS 1×, blocked with 3% bovine
serum albumin for 1 h, and incubated overnight with the respec-
tive primary antibody: LAMP2/CD107b, which detects the three
isoforms of LAMP2 (BD Biosciences), p62/SQSTM1 (Santa Cruz) and
LAMP1 (BD Bioscience). Next day incubation with a Cy3-conjugated
secondary antibody (Jackson ImmunoResearch) was  performed for
2 h and the nucleus was  counterstained with Hoechst 33258.
Microscopic analysis was performed using a Leica TCS SP5 con-
focal laser scanning microscope and a HCX PL APO lambda blue
63× OIL UV objective controlled by LAS AF scan software (Leica
Microsystem, Wetzlar, Germany). Images were taken simultane-
ously and co-localization was determined with the program Fiji
(function Coloc2) using single slices and ROIs. The number of lyso-
somes was  determined with the program Fiji as described before
(Parganlija et al., 2014). Images in the ﬁgures represent maximum
image projections.
Data analysis
Experiments were repeated at least 3 times independently. Val-
ues are presented as mean ± SEM (Standard Error of the Mean).
Statistical difference between means was assessed by the two-
tailed Student t-test when comparing two  groups, and by one-way
ANOVA with Bonferroni’s post hoc test when comparing three
or more groups using the GraphPad Prism software. Statisti-
cally signiﬁcant values are indicated by *p ≤ 0.05, **p ≤ 0.01, and
***p ≤ 0.001.
Results
LAMP3 is detectable in the neuroblastoma cell line SH-SY5Y but
not in brain
Early reports indicate that LAMP3 mRNA is undetectable in
human or mouse brains (Ozaki et al., 1998; Salaun et al., 2003).
However, several genome-wide association studies (GWAS) of PD
have recently identiﬁed the locus MCCC1/LAMP3 as a risk factor for
the disease (Li et al., 2013; Lill et al., 2012; Pihlstrom et al., 2013).
Thus, the expression of Lamp3 was  investigated in a mouse model
that overexpresses -synuclein, a crucial protein in the pathogen-
esis of PD or in control animals with the same genetic background
(wild type). This animal model overexpresses the mutant human
A53T--synuclein under the control of the neuron-speciﬁc prion
promoter. The animals display normal motor activity at 6 months,
but progress to impaired spontaneous movement by 18 months,
without detectable neuronal loss in the nigrostriatal projection
or protein degradation and aggregation problems (Gispert et al.,
2003). Quantitative RT-PCR analysis showed that Lamp3 was unde-
tectable in cerebellum, hippocampus, striatum, and midbrain of
wild type mice between 3 and 20 months old. Similarly, Lamp3
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Table  1
Lamp3 expression in mouse brain regions. Speciﬁc brain regions were dissected, total RNA was  isolated and Lamp3 expression was measured by qRT-PCR.
Genotype or treatment Tissue Age or duration of treatment n Lamp3 (Ct)a Tbp (Ct)a
Wild type Cerebellum 3 months 5 Undetectable 27.35 ± 0.09
Hippocampus 20 months 3 Undetectable 27.76 ± 0.01
Striatum 6 months 6 Undetectable 27.10 ± 0.06
Striatum 20 months 6 Undetectable 27.52 ± 0.10
Midbrain 6 months 6 Undetectable 27.78 ± 0.07
Midbrain 20 months 6 Undetectable 28.18 ± 0.02
A53T--synuclein Striatum 20 months 6 Undetectable 27.32 ± 0.09
Midbrain 6 months 6 Undetectable 27.64 ± 0.12
Midbrain 20 months 6 Undetectable 28.00 ± 0.08
DMSO  Midbrain 24 h 4 Undetectable 27.71 ± 0.12
Epoxomicin Midbrain 24 h 4 Undetectable 27.61 ± 0.06
DMSO  Midbrain 2 weeks 4 Undetectable 27.42 ± 0.04
Epoxomicin Midbrain 2 weeks 4 Undetectable 27.51 ± 0.04
Mouse  lungb 1 25.03 32.11
a Ct values of Lamp3 and Tbp were determined by qRT-PCR using mouse-speciﬁc Lamp3
b Expression of Lamp3 in mouse lung is shown for comparative purposes.
Table 2
Ct values of LAMP genes in SH-SY5Y cells. Total RNA was isolated from cells in control
conditions and genes were detected by qRT-PCR.
Gene Ct valuesa
TBP 26.54 ± 0.68
LAMP1 24.03 ± 0.10































LLAMP3 32.24 ± 0.54
a Ct values were obtained by qRT-PCR in at least 3 independent measurements.
RNA was undetectable in striatum or midbrain of 6- and 20-
onth-old transgenic mice (Table 1).
Since the GWAS are based on human probands, the expression
f LAMP3 was  investigated in post-mortem brain tissue of PD cases
nd age-/gender-matched controls. Braak staging indicated that PD
ases were in stage 6 (Table S1), showing substantial Lewy body and
eurite pathology in the cingulate gyrus. Despite low RNA integrity
ue to postmortem time, qRT-PCR could be successfully performed
or the housekeeping genes EIF4A2,  GAPDH, and TBP. Nevertheless,
nalysis of LAMP3 showed average Ct values of ∼37, close to a
on-speciﬁc signal (Fig. S-1A). Accordingly, comparing the levels
f LAMP3 in PD cases versus controls showed no differences (Fig.
-1B). To determine whether the LAMP3 protein was  present, west-
rn blot analysis was performed. PD samples and controls showed
 strong GAPDH signal, but no detectable LAMP3 protein (Fig. S-
C). These data indicate that LAMP3 is not expressed in the mouse
rain or in the human cingulate gyrus, even when PD pathology is
resent.
Tumor transformation is a factor that correlates with LAMP3
xpression (Kanao et al., 2005; Ozaki et al., 1998). To determine
hether LAMP3 is present in brain cancer cells, the expression
f LAMP1,  2, and 3 was determined in human neuroblastoma SH-
Y5Y cells by qRT-PCR. Table 2 shows that LAMP1 and LAMP2 are
xpressed strongly in SH-SY5Y cells, with Ct values comparable to
hose of the housekeeping gene TBP. In contrast, LAMP3 displays Ct
alues that reﬂect relatively low expression, but still signiﬁcantly
bove non-speciﬁc signals (Ct values >35). This analysis indicates
hat LAMP3 is present in neuroblastoma cells, probably due to its
umorigenic nature as reported for other cell lines (Kanao et al.,
005; Nagelkerke et al., 2011; Pennati et al., 2013).
AMP3 and LAMP2 colocalize in the perinuclear area but not in
he cellular periphery
The different phenotypes of knockout mice lacking either
AMP1 (Andrejewski et al., 1999) or LAMP2 (Tanaka et al., 2000), TaqMan probes.
and the cell-speciﬁc expression pattern of LAMP3 (de Saint-Vis
et al., 1998; Kanao et al., 2005; Ozaki et al., 1998) suggest that these
proteins have distinct functions. Thus, the subcellular localization
of LAMP3 and LAMP2 was compared. A LAMP3-GFP fusion protein
was generated and transiently expressed in HeLa cells; one day
after transfection LAMP2 was visualized by antibody staining and
the co-localization of both proteins was  determined by confocal
scanning microscopy. The images show that LAMP3-GFP colocal-
izes with LAMP2 with a mean Pearson correlation coefﬁcient of
0.78. This occurs mostly in the perinuclear area, while in the cellu-
lar periphery a signiﬁcant number of vesicles are only positive for
either LAMP3-GFP or LAMP2 (Fig. 1A).
A common characteristic of the LAMP family members is
their posttranslational glycosylation. The expected primary size
of LAMP3-GFP without posttranslational modiﬁcations is ∼70 kDa.
Western blot analysis of LAMP3-GFP lysates using an anti-GFP
antibody detected two bands: the main band at ∼90 kDa, and
a weaker band at ∼130 kDa. In deglycosylated samples, LAMP3-
GFP immunoreactivity appeared also in two bands, at ∼70 kDa
and ∼110 kDa, indicating a deglycosylation size shift of ∼20 kDa
(Fig. 1B). These results indicate that LAMP3 exists with different
degrees of posttranslational modiﬁcation: 20 kDa due to posttrans-
lational glycosylation and an additional modiﬁcation of 40 kDa of
unknown nature. In summary, these results suggest that the LAMP
proteins share posttranslational glycosylation, but their partially
overlapping intracellular localization (Fig. 1A) and differential tis-
sue expression (de Saint-Vis et al., 1998; Kanao et al., 2005; Ozaki
et al., 1998; Saftig et al., 2010) suggest distinct functional roles.
LAMP3 is strongly induced by proteasomal inhibition in
neuroblastoma cells
To determine the functional role of LAMP3, several stimuli and
stressors were used to determine their inﬂuence on LAMP3 expres-
sion in neuroblastoma SH-SY5Y cells. Measurement of transcript
levels showed that the following stimuli resulted in the downreg-
ulation of LAMP3:  retinoic acid-induced differentiation, inhibition
of the MEK/ERK pathway with U0126, inhibition of the PI3K/Akt
pathway with LY294002, mitochondrial uncoupling with CCCP, as
well as induction of autophagy by the mTOR inhibitor rapamycin
or serum-/amino acid deprivation with HBSS medium. In contrast,
staurosporine did not affect LAMP3 mRNA expression signiﬁcantly.
The following stressors promoted the induction of LAMP3: block-
age of autophagy with the V-ATPase inhibitor baﬁlomycin A1 or the
PI3K inhibitor 3-methyladenine, and inhibition of the proteasome
with MG132 or epoxomicin (Fig. 2A). The upregulation of LAMP3
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Fig. 1. Differential localization of LAMP3 and LAMP2. (A) HeLa cells were transfected with the plasmid LAMP3-GFP (green) and one day after transfection stained with
an  anti-LAMP2 antibody (red). LAMP3-GFP showed colocalization with the lysosomal protein LAMP2 as indicated by the Pearson correlation coefﬁcient especially in the
perinuclear zone, while in the cellular periphery other vesicles were only positive for LAMP3-GFP or LAMP2 (bar = 10 m).  Quantiﬁcation was  done on three independent
slides with 5 ﬁelds of view/slide. (B) HeLa cells were transfected with LAMP3-GFP. After 24 h protein was collected in deglycosylation lysis buffer and enzymatically N- and



















end  ∼130 kDa), indicating two different degrees of posttranslational modiﬁcation. D
ppeared at the predicted molecular weight of ∼70 kDa corresponding to the prim
he  presence of a posttranslational modiﬁcation resistant to glycosylation. * indicat
fter proteasomal inhibition was rather unusual, because MG132
reatment commonly resulted in downregulation or had no effect
n PD-associated genes (Fig. S-2). Thus, our data suggest that LAMP3
articipates in the stress response to proteasomal inhibition.
In order to determine if these results obtained with a neuroblas-
oma cell line could be replicated in vivo, mouse brains were infused
ith the proteasome inhibitor epoxomicin for 24 h or 2 weeks,
nd the expression of Lamp3 was measured. The inhibitory effect
f epoxomicin at 24 h is evidenced by the upregulation of Sqstm1
sequestosome 1, synonymous to p62) to 1.3-fold (Fig. S-3), while
he effect of epoxomicin at 2 weeks was previously documented as
 ∼60% loss of tyrosine-hydroxylase-positive neurons in the mid-
rain compared to vehicle-infused animals (Subramaniam et al.,
014). As shown in Table 1, Lamp3 expression was undetectable
fter 24 h and 2 weeks of treatment, suggesting that additional fac-
ors as e.g. tumorigenic transformation are needed to induce Lamp3
xpression in the brain.osylation of LAMP3-GFP resulted in a shift of the two  original bands, one of which
ructure of the fusion protein. Another band was detected at ∼110 kDa, suggesting
-speciﬁc band.
Autophagic and proteasomal activity differentially regulate the
expression of LAMP1, LAMP2, and LAMP3
The next question was  if other members of the LAMP fam-
ily are equally affected by proteasomal inhibition or autophagy
induction. Therefore, the expression of LAMP1,  LAMP2 and LAMP3
was measured after starvation or proteasomal inhibition. Incuba-
tion of SH-SY5Y cells in HBSS medium for 24 h had no effect on
LAMP1 expression, resulted in upregulation of LAMP2 (1.6-fold), and
caused downregulation of LAMP3 (0.36-fold) (Fig. 2B). The concen-
tration of the proteasomal inhibitor MG132 was lowered from now
on to 300 nM for 24 h, as opposed to 3 M during 16 h in Fig. 2A, to
diminish cell death. Proteasomal inhibition had no effect on LAMP1
or LAMP2,  and induced a strong upregulation of LAMP3 (10.3-fold)
(Fig. 2C). Importantly, the strong effect of proteasomal inhibition
on LAMP3 expression could be reproduced in an additional cell line:
proteasomal inhibition in HeLa cells resulted also in upregulation
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Fig. 2. LAMP3 mRNA levels were modulated by starvation-induced autophagy and proteasomal inhibition. (A) Relative levels of LAMP3 mRNA were determined by qRT-PCR in
SH-SY5Y cells under different conditions. Cellular differentiation was induced with 10 M retinoic acid (RA) and 3% FCS for 10 days. The following treatments had a duration
of  16 h: control medium with 0.05% DMSO, 10 M U0126, 25 M LY294002 (LY), 10 nM CCCP, 0.5 M rapamycin (Rap), starvation medium (HBSS), 30 nM staurosporine
(Stau),  10 nM baﬁlomycin A (Baf), 10 mM 3-methyladenine (3MA), 3 M MG132, and 1 M epoxomicin (Epo). LAMP3 was downregulated by RA-induced differentiation,
U0126, LY294002, CCCP, rapamycin- and starvation-induced autophagy. Staurosporine did not affect LAMP3. Autophagy inhibition with baﬁlomycin A1 or 3-methyladenine,
and  proteasome inhibition with MG132 or epoxomicin induced LAMP3 upregulation (n = 3). (B) SH-SY5Y cells were cultured in complete (RPMI + 10%FCS) or in starvation
medium (HBSS) for 24 h. Relative mRNA levels of LAMP1, LAMP2, and LAMP3 were determined by qRT-PCR. LAMP1 mRNA levels remained unchanged, LAMP2 mRNA levels






















kn  the presence of 300 nM MG132 or the equivalent concentration of the vehicle (D
RT-PCR. LAMP1 and LAMP2 mRNA levels remained unchanged, and LAMP3 mRNA w
n  = 4–7). Statistically signiﬁcant values of t-tests are indicated by *p ≤ 0.05, **p ≤ 0.
f LAMP3 (3.6-fold), but not of LAMP1 (0.7-fold) or of LAMP2 (0.6-
old) (Fig. S-4). These results imply that in response to proteasomal
ysfunction LAMP3 is speciﬁcally upregulated.
Next, protein expression of LAMP3 was analyzed. The LAMP3
F4087 antibody recognized bands of the expected size in the pos-
tive controls (human lung tissue and HeLa cells overexpressing
AMP3-GFP), but both in SH-SY5Y and HeLa cells a strong non-
peciﬁc signal covered the region of the endogenous LAMP3 band
Fig. S-5A). Usage of other commercial antibodies (Fig. S-5B and C)
r custom-generated LAMP3 antibodies resulted in nonspeciﬁc sig-
als. Thus, it was not possible to conﬁrm the transcriptional data
t the protein level.
AMP3 induction during proteasomal inhibition depends on the
TF4 transcription factor
Previous data showed that LAMP3 induction by different stress-
rs is depending on the UPR transcription factor ATF4 (Mujcic
t al., 2009; Nagelkerke et al., 2013a,b). To determine whether the
TF4 transcription factor controls the expression of LAMP3 during
roteasomal stress, the expression of molecules involved in UPR
nd LAMP genes was measured in cells with and without ATF4
nockdown. SH-SY5Y cells were transfected with ATF4 siRNA or) for 24 h. Relative mRNA levels of LAMP1, LAMP2, and LAMP3 were determined by
bustly induced by proteasomal inhibition compared to the vehicle-treated control
d ***p ≤ 0.001.
control siRNA and then exposed to MG132 or DMSO as control for
24 h. Quantitative RT-PCR analyses showed that MG132 treatment
induced the expression of ATF4 (2.1-fold), LAMP3 (10-fold), as well
as the UPR genes HSPA5 (4.6-fold), and ATF3 (33-fold) (Fig. 3A). The
∼80% reduction of ATF4 in MG132-treated cells correlated with a
reduction of LAMP3,  HSPA5,  and ATF3 expression by 90%, 40%, and
60%, respectively. In contrast, LAMP1 expression was  not affected by
ATF4 knockdown, and although LAMP2 was not induced by MG132
alone, its expression was partially inhibited by ATF4 siRNA (∼0.6-
fold) (Fig. 3B). These data indicate that during proteasomal stress
LAMP3 is induced as part of the UPR in an ATF4-dependent pathway.
In the reverse experiment the possibility that the knockdown of
LAMP3 exacerbates the UPR and feeds-back onto UPR gene regula-
tion was investigated. To this end, SH-SY5Y cells were transfected
with control (CTRL siRNA) or LAMP3-targeted siRNA (LAMP3 siRNA)
before initiating MG132 treatment. Afterwards, gene expression of
the UPR genes HSPA5,  DDIT3,  ATF3 and ATF4 was  determined by qRT-
PCR. Basal levels of LAMP3 were reduced by 50%, and in the presence
of MG132 the 10-fold upregulation was  blunted to 2.3-fold (Fig. 4A).
Only in the case of HSPA5 the silencing of LAMP3 resulted in
further upregulation of the corresponding transcript, thus show-
ing that lack of LAMP3 is not enough to exacerbate generalized
UPR gene expression (Fig. 4B). In contrast to the MG132-induced
154 J.A. Dominguez-Bautista et al. / European Journal of Cell Biology 94 (2015) 148–161
Fig. 3. LAMP3 induction during proteasomal inhibition depends on the transcription factor ATF4. (A) SH-SY5Y cells were transfected either with control siRNA (CTRL siRNA)
or  with ATF4-directed siRNA (ATF4 siRNA) and after 1 d treated for 24 h with 300 nM MG132 or vehicle. Transcript levels of ATF4, LAMP3,  HSPA5,  and ATF3 were determined
by  qRT-PCR. ATF4 was  induced by MG132 and its induction was inhibited with ∼80% efﬁciency in ATF4 siRNA transfected samples. ATF4 knockdown prevented the induction







tot  affected by ATF4 knockdown. LAMP2 was not induced due to proteasomal inhi
tatistical analysis was  performed by ANOVA with Bonferroni’s post hoc test *p ≤ 0.
pregulation of the UPR genes, analysis of lysosomal and
utophagic genes showed either downregulation or no effect in
esponse to MG132 treatment, and this was independent of LAMP3
Table S2).
To substantiate our hypothesis that the UPR is involved in
he induction of LAMP3,  SH-SY5Y cells were incubated with, but its expression was inhibited by ATF4 siRNA during MG132 treatment (n = 3).
 ≤ 0.01, and ***p ≤ 0.001.
thapsigargin or tunicamycin, known ER stressors and activators
of the UPR. Both thapsigargin and tunicamycin treatment resulted
indeed in a signiﬁcant upregulation of LAMP3 and the UPR molecule
HSPA5, but not LAMP1 or LAMP2 (Fig. S-6). Taken together, these
ﬁndings support the notion that LAMP3 is induced as part of the
UPR in SH-SY5Y cells during proteasomal inhibition.
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Fig. 4. LAMP3 regulates HSPA5 gene expression during proteasomal inhibition. (A) SH-SY5Y cells were transfected with control siRNA (CTRL siRNA) or with LAMP3-targeted
siRNA  (LAMP3 siRNA) and after 1 d cells were treated for 24 h with 300 nM MG132 or equivalent concentration of the vehicle DMSO. Relative levels of LAMP3 were determined









eet-up  as in (A), relative mRNA levels of HSPA5,  DDIT3,  ATF3, and ATF4 were determ
pregulation of HSPA5,  DDIT3,  ATF3, and ATF4. Prevention of LAMP3 upregulation r
nalysis was performed by ANOVA with Bonferroni’s post hoc test *p ≤ 0.05, **p ≤ 0.
AMP3 upregulation is contributing to autophagic ﬂux induction
fter proteasomal inhibition
Proteasomal dysfunction prompts compensatory autophagy
Korolchuk et al., 2010; Nedelsky et al., 2008; Park and Cuervo,
013), the unfolded protein response (UPR) being one of the pro-
osed crosstalk pathways between these two systems (Korolchuk
t al., 2010). Therefore, the inﬂuence of LAMP3 on autophagy duringby qRT-PCR in SH-SY5Y cells. MG132-mediated proteasomal inhibition resulted in
d in an increase of HSPA5, but had no effect on the other genes (n = 3). Statistical
d ***p ≤ 0.001.
proteasomal inhibition was  assessed by measuring SQSTM1/p62 at
the transcript and protein level, as well as the formation of LC3-II
as parameters for autophagy and autophagic ﬂux (Mizushima et al.,
2010). SQSTM1was determined in SH-SY5Y cells with and without
LAMP3 knockdown and MG132 exposure. Measurement of SQSTM1
mRNA showed an 11-fold induction upon MG132 treatment, and
this induction was not affected by knockdown of LAMP3 (Fig. 5A).
At the protein level, SQSTM1 was expressed only minimally in
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Fig. 5. SQSTM1 induction and puncta formation is independent of LAMP3. (A) SH-SY5Y cells were transfected with CTRL siRNA or LAMP3 siRNA and after 1 d exposed to 300 nM
MG132  or DMSO for 24 h. SQSTM1 was measured by qRT-PCR. Proteasomal inhibition with MG132 resulted in upregulation of SQSTM1 (n = 3). (B) Cells were transfected and
treated with MG132 as in (A) and total protein was  analyzed by western blot using an antibody against SQSTM1. A representative western blot as well as the densitometric
analysis is shown. SQSTM1 was  strongly induced by MG132 treatment, and the extent of its induction was not affected by silencing of LAMP3 (n = 3). (C) Cells were transfected
and  treated with MG132 as in (A), and stained with an antibody against SQSTM1. The number of SQSTM1 puncta per cell was determined by confocal microscopy. The number
of  puncta per cell was  increased by MG132 treatment, independently of LAMP3 induction. A total of 20–70 cells in at least 5 randomly chosen ﬁelds of view were used in the
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ontrol conditions; upon MG132 treatment its expression
ncreased strongly (∼50-fold) and was not inﬂuenced by the silenc-
ng of LAMP3 (Fig. 5B). Treatment with MG132 increased the
umber of SQSTM1 signals (puncta), which are most probably asso-
iated with LC3-positive autophagosomes (Sahani et al., 2014).
owever, their number was not affected by the knockdown of
AMP3 (Fig. 5C and Fig. S-7A).
Another crucial marker to monitor autophagy is the assess-
ent of LC3-I conversion to LC3-II in the presence and absence of
nhibitors of autophagosome-lysosome fusion, as baﬁlomycin A1
Mizushima et al., 2010). We  showed before that in SH-SY5Y cells a
C3-II band in the absence of baﬁlomycin A1 is not detectable even
n cells starved for more than 12 h (Klinkenberg et al., 2012), prob-
bly due to strong autophagic ﬂux. Therefore, analysis of LC3-II in
H-SY5Y cells was monitored only in the presence of baﬁlomycin
1. As predicted, proteasomal inhibition resulted in an upregula-
ion of autophagic ﬂux (ratio LC3-II/GAPDH) (3.1-fold). Importantly,
iRNA-mediated LAMP3 silencing resulted in an impaired induc-
ion of autophagic ﬂux (1.9-fold) (Fig. 6A), indicating that LAMP3
s necessary for the induction of autophagy upon proteasomal dys-
unction despite unchanged SQSTM1 levels (see Discussion).
As LAMP3 is a lysosomal protein, potential changes in lysosome
umber and distribution after LAMP3 knockdown were assessed.
ells were transfected with LAMP3 siRNA or control siRNA, treated
ith MG132 or DMSO, and immunostained for the lysosomal
arker LAMP1. No signiﬁcant changes were observed in the dis-
ribution or the amount of LAMP1-positive vesicles per cell (Fig. 6B
nd Fig. S-7B). This suggests that the alteration in autophagic ﬂux
uring MG132 treatment is not mediated by changes in lysosomal
umber.
To determine whether the effect of LAMP3 siRNA on autophagic
ux is speciﬁc for proteasomal inhibition, the inﬂuence of LAMP3
n starvation-induced autophagy was measured. Fig. 6C shows
hat the autophagic ﬂux in cells cultured in starvation medium
as not affected by the knockdown of LAMP3.  This indicates that
AMP3 speciﬁcally inﬂuences autophagic ﬂux induced by proteaso-
al  inhibition, but not by starvation.
AMP3 is necessary for cell survival during proteasomal inhibition
As shown above and detailed in the discussion, autophagy
nduction is a fundamental cellular survival response to protea-
omal dysfunction. Given that autophagy induction as a result of
roteasomal inhibition was impaired in LAMP3-silenced cells, the
ole of LAMP3 in cell survival was evaluated. SH-SY5Y cells were
ransiently transfected with the LAMP3-targeted siRNA or a control
iRNA, and either treated with MG132 or DMSO. After 24 h apo-
tosis was quantiﬁed by two methods that determine caspase-3
ctivation. Proteasomal inhibition resulted in a strong induction of
poptosis measured by caspase-3 activity (13.5-fold), which was
urther increased in cells that were previously transfected with the
iRNA targeting LAMP3 (17.8-fold) (Fig. 7A). This result could be
onﬁrmed by measuring the cleavage of PARP, an early substrate of
aspase-3. Proteasomal inhibition resulted in increased appearance
f the 89 kDa PARP fragment, and the prevention of LAMP3 upreg-
lation resulted in a further increase of PARP cleavage (Fig. 7B).
 rescue experiment by transfecting SH-SY5Y cells with LAMP3-
FP prior to MG132 treatment was not successful, due to the low
ransfection efﬁciency of LAMP3-GFP in this cell line.
To determine whether the effect of LAMP3 knockdown on apo-
tosis is speciﬁc for proteasomal inhibition, cells were transfected
ith LAMP3 siRNA and treated for 6 h with the kinase inhibitor stau-osporine, a well-known inducer of apoptosis. As shown in Fig. 7C,
xposure to staurosporine resulted in a strong increase of caspase-
 activity, which was however not inﬂuenced by LAMP3.  These data
oint to a speciﬁc function of LAMP3 in proteasomal inhibition.rnal of Cell Biology 94 (2015) 148–161 157
In summary, our data show that upregulation of LAMP3 in SH-
SY5Y cells is necessary for the response to proteasomal inhibition
in order to promote cell survival.
Discussion
Recent genome-wide association studies of PD have identiﬁed
variants at the locus MCCC1/LAMP3 as risk factors, although LAMP3
was not detected in brain tissue (Akasaki et al., 2004; de Saint-
Vis et al., 1998; Kanao et al., 2005; Salaun et al., 2004). With this
ﬁnding as starting point we  investigated a possible function that
LAMP3 could have in the progression of PD. Neither overexpres-
sion of the mutant human A53T--synuclein nor the infusion of a
proteasomal inhibitor induced the expression of LAMP3 in mouse
brain. Furthermore, LAMP3 mRNA and protein was not detected in
the posterior cingulate gyrus of PD cases and age-/gender-matched
controls. Recently, Murphy and colleagues reported that early and
late cases of PD as well as age-matched controls expressed LAMP3
protein in the anterior cingulate and that there were no signiﬁ-
cant differences between these two  groups (Murphy et al., 2014).
In our hands, the same antibody also detected a band at ∼65 kDa
in HeLa cells. But this signal was not affected by LAMP3 siRNA
transfection or deglycosylation; thus, we  assume that it represents
a non-speciﬁc band (Fig. S-5B). While the expression of LAMP3
in other brain regions should not be ruled out, our data indicate
no direct association of LAMP3 with the neuronal pathomecha-
nisms that are contributing to PD. Further investigation is needed
to understand how the MCCC1/LAMP3 locus contributes to the initi-
ation or progression of PD. Possible mechanisms could include the
participation of LAMP3 in cellular physiology outside the brain, or
the involvement of other genes present in the MCCC1/LAMP3 locus.
In contrast to the absence of LAMP3 in brain, the cell line SH-
SY5Y, originating from a neuroblastoma tumor, expresses this gene.
The LAMP3 expression is probably due to the tumorigenic nature
of the cell line, as LAMP3 is involved in cellular transformation and
invasiveness in cervical, breast, and prostate cancer cells (Kanao
et al., 2005; Nagelkerke et al., 2011; Pennati et al., 2013). In support
of this hypothesis, differentiation of SH-SH5Y cells with retinoic
acid reduced LAMP3 levels by 50%.
Using different pharmacologic modulators, proteasomal
inhibitors were identiﬁed as strong inducers of LAMP3 expres-
sion. Previous reports have shown that the LAMP3 expression is
ATF4-dependent during hypoxia (Nagelkerke et al., 2013a,b). Our
results imply that the mechanism that controls LAMP3 expression
during proteasomal stress is the UPR because (1) knockdown
of the UPR transcription factor ATF4 prevented the induction
of LAMP3 by MG132 treatment, (2) other molecules of the UPR
were induced similar to LAMP3,  and (3) direct activation of the
UPR with thapsigargin or tunicamycin strongly triggered LAMP3,
but not LAMP1 or LAMP2 induction. Thus, our data indicate that
proteasomal inhibition activates LAMP3 expression via the UPR
in neuroblastoma cells. Despite a lot of effort dedicated to this
subject, the induction of LAMP3 at the protein level could not
be determined due to crossreactivity or nonspeciﬁcity of several
commercial LAMP3 antibodies.
Consistent with other reports (Lan et al., 2015; Tang et al., 2014),
analysis of the autophagosome marker LC3-II showed that protea-
somal inhibition promoted enhancement of the autophagic ﬂux.
Silencing of LAMP3 impaired the induction of autophagic ﬂux and
promoted cell death. As indicator of autophagic ﬂux we relied
on the autophagosomal marker LC3-II rather than SQSTM1/p62.
SQSTM1 interacts on the one hand with the ubiquitin moiety in
ubiquitin-tagged protein substrates, and on the other hand with
LC3-II for subsequent autophagic degradation (Lamark et al., 2009).
As can be seen in Fig. 5B and C, the basal levels of SQSTM1 protein
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Fig. 6. Prevention of LAMP3 mRNA upregulation resulted in impaired autophagic ﬂux during proteasomal inhibition. (A) Autophagic ﬂux was analyzed in SH-SY5Y cells with
or  without LAMP3 knockdown either in control conditions (DMSO) or in the presence of 300 nM MG132 for 24 h. Baﬁlomycin A1 was added at a ﬁnal concentration of 10 nM
during the last 2 h of culture. Total protein was analyzed by western blot using an anti-LC3 antibody, and GAPDH as loading control. A representative western blot as well as
the  densitometric analysis is shown. Autophagic ﬂux was impaired by LAMP3 siRNA in MG132-treated cells (n = 3). (B) The number of LAMP1-positive vesicles per cell was
quantiﬁed in cells with or without LAMP3 knockdown and treated with MG132 or DMSO. Cells were ﬁxed, stained with an antibody against LAMP1, and analyzed by confocal
microscopy. The number of LAMP1-positive vesicles was not affected by MG132 treatment or LAMP3 knockdown. A total of 20–70 cells in at least 5 randomly chosen ﬁelds
of  view were used for the quantiﬁcation. A representative image is shown in Fig. S-7B. (C) Autophagic ﬂux was analyzed in SH-SY5Y cells with or without LAMP3 knockdown
either in control conditions (RPMI) or in starvation medium (HBSS) for 2 h. In all cases 10 nM baﬁlomycin A1 was present in the culture. Total protein was  analyzed by
western  blot using an anti-LC3 antibody, and GAPDH as loading control. A representative western blot as well as the densitometric analysis is shown. Autophagic ﬂux was
not  inﬂuenced by LAMP3 siRNA in starved cells (n = 4). Statistical analysis was performed by ANOVA with Bonferroni’s post hoc test *p ≤ 0.05, **p  ≤ 0.01, and ***p ≤ 0.001.
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Fig. 7. Prevention of LAMP3 mRNA upregulation resulted in increased apoptosis during proteasomal inhibition. (A) SH-SY5Y cells were transfected with CTRL siRNA or LAMP3
siRNA  and after 1 d exposed to 300 nM MG132 or DMSO for 24 h. Caspase-3 activity analysis was performed as indicated in materials and methods. Knockdown of LAMP3
resulted in an increase of MG132-induced caspase-3 activity. Results were normalized to protein amount and shown relative to DMSO + CTRL siRNA (n = 5). (B) SH-SY5Y cells
were  transfected with CTRL siRNA or LAMP3 siRNA, cultured overnight and then exposed to 300 nM MG132 or DMSO for 24 h. Cleavage of Poly-ADP Ribose Polymerase (PARP)
was  determined by western blot. Increased cleaved PARP 89 kDa was observed upon proteasomal inhibition, and a further increase was  observed in LAMP3 siRNA-transfected
cells  (n = 4). (C) SH-SY5Y cells were transfected with CTRL siRNA or LAMP3 siRNA and after 1 d exposed to 30 nM staurosporine or DMSO for 6 h. Caspase-3 activity analysis
was  performed as indicated in materials and methods. Knockdown of LAMP3 did not affect caspase-3 activity induced by staurosporine. Results were normalized to protein
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ere very low and increased strongly after MG132-triggered pro-
easomal inhibition. It seems likely that an additional effect due to
AMP3 silencing would not be detectable in this strong reaction.
The mechanism that mediates the induction of autophagic ﬂux
ollowing proteasome inhibition seems to depend on the UPR. In
upport of this hypothesis, it was reported that the transcription
actor ATF4 mediates autophagy in response to the proteasome
nhibitors bortezomib and oprozomib in multiple myeloma and
ther cancers (Rzymski et al., 2009; Zang et al., 2012). Therefore,
e propose the following scenario in our model: proteasomal inhi-
ition with MG132 activates the ATF4 pathway of the UPR, thus
riving LAMP3 expression and promoting autophagic ﬂux. During
roteasomal inhibition enhancement of the autophagic pathway
cts as compensatory response to degrade accumulated protea-
ome substrates. It is important to stress MG132-mediated ATF4
ignaling pathway is primarily targeting LAMP3 and not LAMP1,
nd only slightly inﬂuencing LAMP2. Given that LAMP3 and LAMP2
ignals did not entirely colocalize in immunoﬂuorescence and
hat the number, appearance and distribution of lysosomes and
62-positive puncta/autophagosomes did not change after LAMP3
nockdown, it is tempting to speculate that LAMP3 has a role
n autophagosome maturation and/or autophagosome-lysosome
usion.
In case of LAMP3 deﬁciency, autophagy induction is impaired,
nd the autophagy-lysosomal pathway is overtaxed resulting in
urther accumulation of non-degraded substrates. With both of the
ajor degradation pathways dysfunctional, apoptosis is enhanced.
This hypothesis is supported by previous studies revealing the
articipation of LAMP3 in autophagy and cellular viability in dif-
erent cancer cells. One report showed that breast cancer cells
esistant to the cytostatic drug tamoxifen expressed 7-times more
AMP3 mRNA than sensitive cells, and exhibited signiﬁcantly higher
utophagic activity. Importantly, siRNA-mediated LAMP3 silencing
esulted in autophagy inhibition and restored tamoxifen sensitivity
Nagelkerke et al., 2014). Furthermore, prostate cancer cells resis-
ant to the chemotherapeutic cisplatin can be resensitized to the
rug by the knockdown of LAMP3.  This effect seems mediated by
he impairment of autophagic ﬂux (Pennati et al., 2013).
As recent data indicate that autophagy and the ubiquitin-
roteasome system have crucial roles for tumor development and
etastasis (Erraﬁy et al., 2013; Qiang et al., 2014; Vogl et al., 2014),
ur ﬁndings that LAMP3 participates in the response to proteaso-
al  dysfunction are relevant for cancer research. The proteasomal
nhibitor bortezomib is approved for the treatment of multiple
yeloma, but its effectiveness is limited against breast tumors
Combaret et al., 2008; Mujtaba and Dou, 2011). In addition, cancer
ells often develop resistance to chemotherapy (Furfaro et al., 2014)
nd the resistance mechanisms include the induction of the UPR
nd autophagy (Milani et al., 2009). Accordingly, LAMP3 could be
nvolved in the development of resistance to proteasomal inhibitors
uring chemotherapy.
In conclusion, we report a previously unknown transcriptional
pregulation of LAMP3 expression after proteasomal stress, which
s contributing to promote autophagy and cell survival.
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